IO Biotech
IOBT
IOBT was delisted on the 6th of April, 2026.
20 hedge funds and large institutions have $30.7M invested in IO Biotech in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
11% more funds holding
Funds holding: 18 → 20 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.76% less ownership
Funds ownership: 41.57% → 39.81% (-1.8%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
35% less capital invested
Capital invested by funds: $47.4M → $30.7M (-$16.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$269K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$39.5K |
| 3 |
Renaissance Technologies
New York
|
+$19K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$14.9K |
| 5 |
RWMG
Redwood Wealth Management Group
Medford,
New Jersey
|
+$5.82K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$921K |
| 2 |
Morgan Stanley
New York
|
-$314K |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$270K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$269K |
| 5 |
AC
Armistice Capital
New York
|
-$250K |
IOBT Hedge Fund Activity: Q2 2024 in Review
20 of the 6,931 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q2 2024, worth a combined $30.7M — down 35% from $47.4M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new IOBT positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $269K. The largest seller was Novo Holdings A/S, cutting an estimated $921K.
- 20 institutional investors held IO Biotech (IOBT) as of Q2 2024, up from 18 in Q1 2024.
- Funds reported $30.7M of IO Biotech stock for Q2 2024, down 35% quarter-over-quarter.
- 3 funds opened new IO Biotech positions in Q2 2024 and 1 closed out, a net change of +2 holders.
- The largest IO Biotech buyer in Q2 2024 was Soleus Capital Management, an estimated $269K added.
- The largest IO Biotech seller in Q2 2024 was Novo Holdings A/S, an estimated $921K sold.
Based on aggregated 13F filings for Q2 2024.